Cancers' sweet tooth may be weakness
Researchers at Winship Cancer Institute have discovered a common switch governing cancer cells' glucose usage, which could lead to new treatments.
Researchers at Winship Cancer Institute have discovered a common switch governing cancer cells' glucose usage, which could lead to new treatments.
Researchers have successfully transplanted genetically modified hematopoietic stem cells into mice, allowing their developing red blood cells to produce a critical lysosomal enzyme and preventing or reducing organ and central nervous system damage from Hurler's syndrome. This approach has the potential to improve treatment options for ...
A new study suggests that green tea extract can reduce the risk of oral cancer, with patients who presented with mild to moderate dysplasia having a longer time to develop oral cancer if they took green tea extract. However, more research is needed to confirm its long-term prevention effects.
Rhode Island Hospital has received a $11 million NIH grant to study stem cell biology and tissue regeneration in lung and marrow diseases. The research will focus on determining the true phenotype of marrow stem cells and their fate as tissue.
The American Society of Hematology recognizes Stuart H. Orkin, MD, and Arthur W. Nienhuis, MD, for their significant contributions to mentoring in hematology. Drs. Orkin and Nienhuis will receive the Mentor Award for Basic Science and Clinical Investigation, respectively.
Arthur Nienhuis, M.D., of St. Jude Children's Research Hospital, received the 2009 ASH Mentor Award for his dedication to mentoring trainees and colleagues. His expertise in bone marrow transplantation and gene therapy paved the way for many advances in hematological disorders.
A new study demonstrates the effectiveness of immunotherapy using specialized white blood cells to prevent or treat EBV-lymphoma in patients who have received a hematopoietic stem cell transplant. The therapy achieved sustained complete remission in 85% of treated patients and long-term protection for up to nine years.
A new study aims to prevent brain complications in children with sickle cell disease by comparing two treatments: standard therapy of monthly blood transfusions and chelation vs. a daily dose of hydroxyurea and monthly phlebotomy. The goal is to reduce the risk of first strokes in high-risk patients with sickle cell anemia.
The National Cancer Institute funds a new $13 million cancer research center at Cornell University, led by Harold Craighead. The center will focus on using nanobiotechnology and other physical science approaches to advance cancer research.
The hospital received a total of 69 grants across multiple departments, focusing on cancer research, cardiovascular diseases, and sleep apnea management. BIDMC scientists will investigate innovative methods to heal broken bones, develop new cancer therapies, and improve sleep health.
A new type of genetic change, a second copy of an entire gene, has been identified as a cause of familial chordoma, a devastating and rare form of cancer. The T (Brachyury) gene duplication was found in patients with the disease, but its exact mechanism is unknown.
Two nurses, Motria A. Lonchyna and Taryn M. Edwards, are awarded Lundbeck Neonatal Nursing Career Path scholarships to advance their education and become neonatal nurse practitioners. The program supports clinical neonatal nurses who seek to improve the care of neonates, infants, and their families.
Recent findings published online first in Cancer Research show that obesity is associated with increased incidence and mortality of leukemia in children. The study reveals that fat cells can block chemotherapy drugs from reaching cancerous cells, leading to reduced treatment effectiveness.
Researchers have discovered an experimental compound that selectively kills cancerous B lymphocytes while allowing normal B cells to survive. The study found that K252a disrupts a key signaling pathway involved in the growth of lymphoma cells, offering new hope for treating non-Hodgkin lymphoma.
A new study shows that anemic patients with myelodysplastic syndromes (MDS) can gain long-term benefits from erythropoietin and a myeloid growth factor, with improved survival rates and overall quality of life compared to those receiving supportive care alone.
A new study published in The Journal of Nuclear Medicine shows that PET/CT scans with the imaging agent choline can detect recurring prostate cancer sooner than conventional imaging technologies. Researchers found a strong association between PET/CT detection and PSA levels, and suggest using specific criteria to reduce unnecessary scans.
Researchers analyzed 17,398 patient records and found only 14 real disease associations with MGUS, not 61 as previously reported. This finding may reduce unnecessary testing and treatment for patients with MGUS.
Researchers at Stanford University Medical School have discovered that leukemia stem cells can escape detection by co-opting a protective molecular badge used by normal blood stem cells. The molecule, CD47, protects the leukemia stem cells from macrophages, allowing them to evade the immune system. Studies found that patients with high...
A study by MU researchers found that cancer survivors experience mild decreases in skills like verbal fluency and problem-solving ability, impacting their daily lives. The researchers identified specific interventions, such as pharmaceuticals and cognitive behavior techniques, to help patients manage these challenges.
Research found that African Americans with HIV who have a genetic variation and low white blood cell count have slower disease progression rates. This study suggests a unique survival advantage for African Americans with HIV if they possess both a DARC variation and leukopenia.
Recent JAMA studies on brain cancer and altered genes have made significant progress in understanding the root causes of this deadly disease. Researchers identified seven genes linked to survival among glioblastoma multiforme patients, paving the way for potential new therapies.
A new chemotherapy regimen, ABVE-PC, has been identified as a successful treatment for pediatric Hodgkin lymphoma, reducing long-term risks and improving survival rates. The treatment delivers dose-dense drug delivery while minimizing cumulative doses, resulting in lower toxicity and improved outcomes.
The American Society of Hematology is honoring six scientists for their significant contributions to hematologic diseases, including the diagnosis and treatment of lymphomas and leukemia. The awards recognize pioneering research achievements and outstanding leadership in advancing the field of hematology.
Researchers at Stanford University School of Medicine have identified a novel connection between the telomerase molecule and the Wnt pathway in stem cell regulation. Overexpression of telomerase's TERT protein enhances Wnt-inducible genes, suggesting a potential new target for cancer therapies.
Researchers have found a way to obtain large numbers of hematopoietic stem cells from human term placentas, which is an order of magnitude larger than those obtained from cord blood. The findings demonstrate that human term placentas are a high-capacity source of live and functional hematopoietic stem cells.
A study of 678 pesticide users found a double risk of developing MGUS compared to the general population. The research suggests exposure to certain pesticides increases the risk of this abnormal blood condition, which requires lifelong monitoring as it can lead to multiple myeloma.
A study published in Nature found that fat cells in bone marrow suppress blood production, making it harder for patients to recover from chemotherapy or radiation. Blocking this fatty infiltration could enhance blood recovery after transplant.
A study from Northwestern University found that Cremophor-based paclitaxel caused life-threatening allergic reactions in 38% of patients, leading to 109 deaths. The solvent is believed to trigger severe reactions, even in patients with premedication.
Dr. Aileen Go has won a prestigious Amgen Foundation Fellowship grant to study treatment options for older leukemia and lymphoma patients. The research aims to develop a reduced-intensity chemotherapy regimen and methods to boost stem cells for patients aged 55-75.
Women with excessive menstrual bleeding may have underlying bleeding disorders. The consensus conference recommends hematologic evaluations to diagnose conditions like Von Willebrand Disease, which affects 74-92% of women with menorrhagia.
A protein that maintains cell 'stemness' has been linked to various advanced human cancers, including liver cancer, ovarian cancer, and Wilm's tumor. Increasing its production can prevent mature tumor-suppressing microRNAs from maturing, leading to a more cancerous state.
A Stanford University study found that disrupting the interferon pathway, a critical immune signaling mechanism, can lead to cancer progression and impaired immune response. This defect was detected in patients with breast, melanoma, and gastrointestinal cancers, suggesting a possible explanation for treatment failures.
A phase III study found that adding an antibody-based therapy improved the survival rate of children with high-risk neuroblastoma by 66%, increasing their chances of living disease-free for at least two years. The therapy targets a specific glycan on cancer cells, enabling immune cells to attack and kill them.
Researchers have discovered that a beating heart and blood flow are necessary for the development of the blood system, which relies on mechanical stresses to cue its formation. Compounds that modulate blood flow had a potent impact on the expression of a master regulator of blood formation, known as Runx1.
A new study published in American Journal of Hematology finds that iron chelation therapy is not a reliable predictor of patient survival. Instead, degree of anemia and need for red blood cell transfusion at diagnosis are stronger predictors.
Researchers are developing a strategic approach to studying metastasis, targeting the molecular and cellular players that mediate changes at future sites of metastasis. This could lead to new cancer treatments that target each step along the metastatic pathway.
Researchers have identified a key molecule called Liar that leads other molecules into the nucleus of blood cells, offering a potential treatment for cancer. A cellular enzyme known as Lyn has also been found to 'turn on' blood cell development, highlighting a new target for cancer therapy.
Researchers at the University of Texas M. D. Anderson Cancer Center have discovered a new drug that inhibits neuroblastoma blood supply, reducing tumor growth by 75%. The drug, AMD3100, blocks interaction between SDF-1a and its receptor CXCR4, preventing tumors from growing rapidly by disrupting their blood supply.
Researchers at the University of Texas M. D. Anderson Cancer Center have discovered a new drug combination that significantly hinders neuroblastoma tumor growth in pre-clinical tests. The combination of vandetanib and 13-cis-retinoic acid reduced tumors by 86 percent, offering new hope for children with this childhood cancer.
Researchers at M. D. Anderson Cancer Center have discovered a drug, AZ23, that reduces AML cell burden by 50% in mice with no immune system. The study also found 60% of treated mice had long-term survival without leukemia cells.
A new cancer drug, 3-BrOP, has been found to reduce neuroblastoma growth by 75 percent in pre-clinical studies. The drug works by blocking the main energy source, glucose, thereby starving cancer cells and disrupting their ability to grow.
A comprehensive review of medical literature by experts found no evidence supporting beneficial effects from blood transfusions. Studies show associations with higher rates of complications like heart attack, stroke, and kidney failure, highlighting the need for restricted practice and safer storage methods.
Scientists have successfully reprogrammed blood cells into cells that mimic embryonic stem cells, opening up new avenues for research and potential treatment of diseases. The discovery provides an accessible source of stem cells, which can be used to study various diseases and develop new therapies.
Researchers at the Mayo Clinic have formulated a treatment combination that destroys up to 65% of pancreatic tumor cells in laboratory tests. The combination of rapamycin and panobinostat acts synergistically, offering new opportunities for patients with pancreatic cancer.
Researchers at Michigan State University have developed a new method for producing cancer-fighting paclitaxel using natural enzymes, potentially reducing chemical byproducts and increasing efficiency.
A Virginia Tech and Wake Forest University study found that altering taste and smell can negatively impact cancer patients' survival chances. Researchers identified management strategies to improve taste and odor abnormalities in cancer patients.
Scientists have discovered that amniotic fluid contains a new source of stem cells with potential therapeutic applications. These cells, known as AFKL cells, can generate all blood cell lineages in experiments and exhibit self-renewal capabilities, similar to other stem cells.
Researchers at Emory University have discovered that DNA repair enzymes can relocate to specific areas of the cell in response to oxidative stress, which is linked to various human diseases. This finding could lead to the development of anti-cancer drugs that target DNA repair mechanisms.
A breakthrough study has revealed that blood stem cells produce chemical signals of their own that influence their attachment to the bone marrow or migration into the circulatory system. This discovery holds implications for improving leukemia treatment and artificially culturing infection-fighting immune cells.
Researchers at UNC School of Medicine have discovered that TH17 cells, a subset of immune cells, can cause transplant rejection. The study's findings may lead to the development of targeted therapies to prevent graft-versus-host disease, which is a major complication of transplants.
Researchers at the Medical College of Wisconsin Cancer Center have discovered a mechanism to limit graft-versus-host disease in bone marrow transplant patients while preserving their leukemia-killing effects. Targeting interleukin 23, an immune substance secreted by donor marrow cells, may be a viable way to achieve this balance.
Research suggests mice without AT1A protein have a significantly prolonged lifespan. This is attributed to reduced cellular oxidation, contributing to aging. Additionally, studies investigate the role of MT1-MMP in regulating hematopoietic progenitor cells' release from bone marrow.
A study published by researchers at Rhode Island Hospital found that parents of childhood cancer survivors continue to need information about the late effects of treatment, which can include memory and concentration problems. The study suggests that early provision of this information may help prevent parental distress and recommends t...
A new study suggests that green tea components may negate the effects of bortezomib (Velcade) in patients taking this medicine. The EGCG polyphenol in green tea bound to boronic acid-containing compounds like bortezomib cancels out their antitumor effects.
Researchers at Stanford University School of Medicine have identified a protein called TCAB1, which is crucial for telomerase to repair the ends of chromosomes. This discovery may lead to new anti-cancer therapies by blocking the inappropriate expression of TCAB1 in human cancer cells.
Researchers successfully used an engineered herpes virus to block tumor formation in mice by targeting and killing apparent cancer stem cells. The study suggests that early-stage cancer precursor cells with stem-cell-like properties may explain how some cancers form and are treatment resistant.
National Lung Cancer Partnership awards I-Ching Wang a Career Development Award to study FoxM1, a protein linked to aggressive lung cancer growth. The grant aims to support protein-directed therapies and control the leading US cancer killer. Dr. Wang's research will help combat underfunding in federal lung cancer research.
The National Lung Cancer Partnership and LUNGevity Foundation have awarded $100,000 research grants to Prasad Adusumilli and Lee Goodglick. Dr. Adusumilli's study will investigate visceral pleural invasion, while Dr. Goodglick's research focuses on estrogen's role in lung cancer.
Researchers at Memorial Sloan Kettering Cancer Center found that elevated p53 levels maintain a cell's dormant state, making it resistant to chemotherapy and radiation. Targeting specific genes involved in quiescence may enhance anticancer effects.
Researchers at UC Davis Cancer Center have discovered a molecule called LXY1 that targets glioblastoma, a deadly form of brain cancer. The molecule binds to alpha-3 integrin on cancer cells, allowing for direct delivery of treatments and sparing normal tissues.